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Background: Early glucosteroid treatment in preterm infants has a negative impact on physical 
growth and development. So far, data on dexamethasone effect on the GH/IGF axis and the 
clinical outcome are conﬂ  icting.
Objective: Therefore, we studied the effect of dexamethasone treatment on parameters of 
somatic growth and on the secretion of insulin like growth factors (IGFs) and insulin like growth 
factors binding proteins (IGFBPs) in preterm infants.
Methods: In 75 preterm infants somatic development was assessed at birth and after 3 months 
of corrected age. IGF-I/II and IGFBP-1-3 were measured at the same time. According to 
their treatment regime the infants were assigned to the dexamethasone treated or the non-
treated group.
Results: At 3 months the 13 infants with dexamethasone had a lower body weight, slightly 
lower body length and a lower head circumference. IGF-II (464.4 ± 97.4 vs 638 ± 201.4 μg/l, 
p = 0.001) and IGFBP-3 (1800 ± 426 vs 2105 ± 547 μg/l, p = 0.045) were signiﬁ  cantly reduced 
under the inﬂ  uence of glucocorticoids, whereas IGFBP-1 was elevated (59.6 ± 61.0 vs 21.1 ± 
21.7 μg/l, p = 0.002). The ratio IGFBP-3/(IGFBP-1 + 2) was reduced in the dexamethasone 
group (1.827 ± 0.868 vs 3.098 ± 1.898 μg/l, p = 0.016), implying a signiﬁ  cant retardation in 
the somatic development.
Conclusion: Dexamethasone impairs IGF and IGFBP secretion and stimulates IGFBP-1, an 
inhibitor of IGF-I. These pathways might contribute to alterations of the GH/IGF axis, particu-
larly the ratio IGFBP-3/(IGFBP-1 + 2).
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Introduction
Dexamethasone is a potent glucocorticoid commonly used in the prevention and 
treatment of chronic lung disease of prematurity. However severe side effects are of 
clinical concerns (Bloomﬁ  eld et al 2001).
In 1998, Yeh et al reported a signiﬁ  cant increase of neurological dysfunction in 
preterm infants treated with dexamethasone, in boys growth was reduced, additionally 
(Yeh et al 1998). In consequence, glucocorticoid-therapy in neonatal patients was 
critically re-evaluated: Between 1994 and 2001 the use of dexamethasone dropped 
from 22% to 6%. Chronic lung disease increased from 13% to 17%, whereas neonatal 
mortality declined from 21% to 15% (Shinwell et al 2003).
Postnatal therapy with glucocorticoids result in favorable and non-favorable con-
sequences: Ventilation time and the rate of bronchopulmonal dysplasia are reduced 
(Tsukahara et al 1999; Sweet and Halliday 2000), whereas the risk for impaired 
neurological development, cerebral paresis, metabolic disorders, hypertrophic cardio-
myopathy, reduced growth and perforations of the gastrointestinal tract is increased Biologics: Targets & Therapy 2007:1(4) 450
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(Romagoli et al 1999; Sweet and Halliday 2000; Stark et al 
2001). Dexamethasone treatment within the ﬁ  rst 24 hours 
did not inﬂ  uence survival or lung disease in preterm infants 
between 500 g and 1000 g (Stark et al 2001).
According to Halliday, the negative impact of dexametha-
sone becomes particularly evident when applied within the 
ﬁ  rst 96 hours of life (Halliday 2004). In contrast, the moderate 
use of glucocorticoids beginning at 7–14 days after birth 
might result in a beneﬁ  cial outcome at the age of 15 years in 
former preterm infants with a birth weight  1250 g (Gross 
et al 2005).
The potential growth restricting effects of dexamethasone 
may be mediated via suppression of the IGF axis. Both dexa-
methasone dose and treatment regimen inﬂ  uence circulating 
IGF-1 and IGFBP-3 levels (Bloomﬁ  eld et al 2001).
Postnatal dexamethasone therapy inﬂ  uences IGFBPs 
concentrations: within the ﬁ  rst 8 weeks of life IGFBP-3 
and phosphoisoforms of IGFBP-1 were reduced, the latter 
only in children with elevated insulin levels (Kajantie 
et al 2002). Growth hormone and IGFBP-1 concentrations 
were decreased in preterm children with bronchopulmonal 
dysplasia two days after the beginning of dexamethasone 
treatment compared to pre-dexamethasone levels (Huysman 
et al 2003).
IGFBP-1 mRNA secretion was induced by glucocorti-
coids in different animal models by various pathways (Luo 
et al 1990; Suwanichkul et al 1994; Suh et al 1995; Suh and 
Rechler 1997; Uchijima et al 1999; Lewitt 2001; Gan et al 
2005).
Objective
Early glucocorticoid treatment might alter infants growth 
via the IGF/IGFBP axis. We therefore studied the inﬂ  u-
ence of dexamethasone on the clinical outcome and on the 
secretion of IGFs and IGFBPs in preterm infants after of 
3 months.
Methods
Patients
75 preterm infants of our neonatal intensive care were 
included in this investigation. Blood was drawn at the second 
day of life and at the corrected age of 3 months. The following 
data were collected and analysed: gestational age, auxologic 
parameters (body weight, length, and head circumferences), 
mode of cardiopulmonary adjustment (APGAR scores, pH of 
umbilical vessels, oxygen saturation), therapeutic strategies 
(respiratory support).
The patients were assigned to the dexamethasone-treatment 
group or non-treatment group depending, if they received 
treatment with glucosteroids or not. Dexamethasone treat-
ment (n = 13) was initiated because of bronchopulmonary 
dysplasia (n = 8) or long-term ventilation with expected 
difﬁ  culties during the weaning from mechanical ventilation 
(n = 5), respectively.
Glucocorticoid treatment was performed as a 3-day 
tapering course of dexamethasone with a total dose of 1.35 
mg/kg according to Garland et al given between the 2nd and 
4th week after birth (Garland et al 1999).
After discharge from the hospital, the formerly risk-
infants underwent controls to monitor development and 
identify developmental deviations during a short hospital stay 
(2–3 days) at the corrected postnatal age of three months.
Infants with congenital malformations, inherited metabolic 
disorders, and infants of diabetic mothers were excluded.
Measurements of IGF and IGFBPs
Venous blood samples (residual volumes from routine 
checks) were investigated.
Samples for the ﬁ  rst cross-section analysis (“after birth”) 
were taken on the second day after birth. All venous blood 
samples were taken at 07.00 am, the infants received their 
last enteral feeding between 04.30 and 05.00 am. IGFs and 
IGFBPs were evaluated using commercially available radio-
immunoassays (IGF-I, IGFBP-1, IGFBP-3: Fa. Mediagnost, 
Tübingen, Germany; IGF-II, IGFBP-2: Fa. DSL, Sinsheim, 
Germany).
The ratio IGFBP-3/(IGFBP-1 + 2) was estimated as a 
marker for the shift from fetal to adult IGF pattern described 
earlier (Hübler et al 2006).
Basal growth hormone (GH) levels were not determined 
because of the strong ﬂ  uctuation of basal GH values.
Statistical analysis
Statistical analysis was conducted using the SPSS release 
12.0 statistics package (SPSS Inc., USA). Values are shown 
as percentage or mean + standard deviation (SD), as indi-
cated. The Mann-Whitney U-test was used for statistical 
determinations, with p   0.05 considered as signiﬁ  cant.
The study was approved by the ethics committee of the 
Friedrich-Schiller-University of Jena (No. 0381-11/99).
Results
At birth, the infants treated with dexamethasone had a 
smaller head circumference, lower APGAR scores, a longer Biologics: Targets & Therapy 2007:1(4) 451
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ventilation time and needed O2 supplementation for a longer 
time (p   0.05, Mann-Whitney test).
After 3 months body weight and head circumference 
were still signiﬁ  cantly reduced in the dexamethasone group 
(p   0.05, Mann-Whitney U test) (Table 1).
Dexamethasone treatment was related to reduced IGF-II 
and IGFBP3 secretion and to an increased IGFBP-1. No 
signiﬁ  cant differences were found for IGF-I and IGFBP-2 
(p   0.05, Mann-Whitney U test) (Table 2).
IGFBP-1 secretion was signiﬁ  cantly enhanced by dexameth-
asone treatment, both in the infants with or without broncho-
pulmonary dysplasia (BPD). In contrast, BPD did not inﬂ  uence 
the IGFBP-1 levels neither in the treated nor in the non-treated 
group (p   0.05, Mann-Whitney U test) (Figure 1).
The ratio IGFBP-3/(IGFBP-1 + 2) was signiﬁ  cantly 
reduced in the infants with glucocorticoid administration 
(p   0.05, Mann-Whitney U test) (Figure 2).
Discussion
Dexamethasone has a negative impact on the somatic 
development in preterm infants. At the age of 3 months 
steroid treated neonates had a signiﬁ  cantly reduced body 
weight and head circumference and tend to be smaller. 
After stopping dexamethasone daily weight gain, occipital-
frontal circumference and crown-rump length improved 
signiﬁ  cantly in ventilated babies with BPD in a Canadian 
investigation. The weekly dose of dexamethasone was 
correlated negatively with all physical growth measures 
(Skinner et al 1997).
In piglets dexamethasone signiﬁ  cantly reduced absolute 
gain in weight and length. At least in parts, this effect could 
be reversed by growth hormone, which indicates a serious 
negative impact of glucosteroids on the growth hormone/IGF 
axis (Ward et al 1998). Dexamethasone treatment for chronic 
lung disease restricts linear growth, which might be medi-
ated via systemic effects on the IGF-I axis. Glucocorticoid 
treatment in general and speciﬁ  cally the dexamethasone dose 
reduce serum IGF-I and IGFBP-3 signiﬁ  cantly (Bloomﬁ  eld 
et al 2001).
In the dexamethasone treated children the secretion 
of IGF-II and IGFBP-3 was signiﬁ  cantly reduced after 3 
months of life, whereas IGF-I levels were only slightly, but 
not signiﬁ  cantly reduced. Kajantie et al could demonstrate 
similar ﬁ  ndings for IGFBP-3 during the ﬁ  rst 2 months 
(Kajantie et al 2002). Off steroid treatment, mean serum 
IGF-I and IGFBP-3 increased in a cohort of 10 ventilated 
infants with BPD, the weekly dose of dexamethasone 
showed no correlation with growth factors in this investiga-
tion (Skinner et al 1997).
In human ﬁ  broblast dexamethasone blocks IGFBP-3, 
IGFBP-4 and IGFBP-5 mRNA transcription (Connover et al 
1995), in hepatocytes IGF-I mRNA (El-Khattabi et al 2003). 
So, glucosteroids interfere with the GH/IGF transcription 
axis on the cytoplasmatic level.
In the infants treated with dexamethasone IGFBP-1 levels 
were signiﬁ  cantly enhanced, irrespectively if they were 
diagnosed BPD or not.
Kajantie et al (2002) reported reduced IGBP-1 
phosphoisoforms in children with elevated insulin 
Table 1 Birth characteristics and anthropometric measurements 
at three months of corrected age
Parameter  Systemic glucocorticoid   Mann- 
 treatment    Whitney  U
 no  (n  = 62)  yes (n = 13)  (p-value)
At birth     
  Gestational age (weeks)  33.3 ± 2.0  31.2 ± 3.9  0.050
  Body weight (g)  1831 ± 467  1521 ± 631  0.081
  Body length (cm)  42.9 ± 3.9  40.4 ± 5.3  0.085
 Head  circumference  30.4  ± 2.6  28.1 ± 3.5  0.033*
 (cm) 
  APGAR after 1 minute  6.5 ± 1.8  4.7 ± 2.5  0.013*
  APGAR after 5 minutes  8.1 ± 1.3  6.8 ± 1.8  0.010*
 Ventilation  (hours)  46.3  ± 165.4  300.6 ± 449.4  0.001*
 O 2-supplementation 5.2  ± 20.4  24.6 ± 36.4  0.001*
 (days) 
  pH of the umbilical  7.28 ± 0.06  7.23 ± 0.11  0.138
 artery 
At 3 months     
  Body weight (g)  5672 ± 990  4874 ± 1175  0.024*
  Body length (cm)  59.9 ± 4.3  58.0 ± 6.1  0.354
 Head  circumference  40.2  ± 2.1  39.1 ± 2.0  0.037*
(cm)
Daily weight gain (g/day)  28.1 ± 4.9  24.9 ± 5.7  0.100
Daily length gain (cm/day)  0.12 ± 0.02  0.12 ± 0.02  0.677
Daily head growth  0.072 ± 0.015  0.073 ± 0.015  0.098
(cm/day)
Table 2 Insulin-like growth factors and IGF binding proteins at 
three months of corrected age
Parameter Systemic  glucocorticoid  Mann-
 treatment   Whitney  U
 no  (n  = 62)  yes (n = 13)  (p-value)
IGF-I [μg/l] 73.3  ± 27.7  69.1 ± 34.4  0.520
IGF-II [μg/l] 638.4  ± 201.6  464.4 ± 97.4  0.001*
IGFBP-1 [μg/l] 21.1  ± 21.7  59.6 ± 61.0  0.002*
IGFBP-2 [μg/l] 842.2  ± 392.8  1119.0 ± 840.1  0.212
IGFBP-3 [μg/l] 2105  ± 547  1800 ± 426  0.045*Biologics: Targets & Therapy 2007:1(4) 452
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secretion. However, neither the age of the children during 
glucocorticoid therapy nor the impact of the child’s age on 
the IGFBP-1 concentration within the ﬁ  rst 2 months of life 
was addressed in their investigation. But, both factors might 
be of relevant inﬂ  uence. Dexamethasone seems to induce 
IGFBP-1 secretion with a latency of some weeks after 
application. Five days after dexamethasone and colostrum 
application IGF-I increased and IGFBP-1 and IGFPBP-2 
decreased in neonatal calves. According to Sauter et al this 
might be the expression of a maturation of the somatotropic 
axis (Sauter et al 2003). IGFBP-1 was reduced 1 and 
2 weeks after dexamethasone and GH therapy, but 7 weeks 
after treatment IGFBP-1 concentrations were signiﬁ  cantly 
elevated (Hammon et al 2003).
In contrast to our data, Huysman et al found a reduction 
of IGFBP-1 only 2 days after the beginning of dexametha-
sone application in preterm infants with BPD on ventilation 
(Huysman et al 2003). It remains to speculate that Huysman’s 
data reﬂ  ect only a very short term effect of the steroids on the 
IGFBP-1 secretion, whereas our ﬁ  ndings integrate a longer 
and more sustainable effect. IGFBP-1 is known to have a 
negative effect on the function of IGF-I. IGFBP-1 is lower in 
infants AGA (appropriate for gestational age) than in IUGR 
(intrauterine growth retardation) with catch up growth and 
even lower compared to those IUGR without catch up growth 
(Öszkan et al 1999).
In several animal models cascades of IGFBP-1 mRNA 
could be induced by stimulation of IGFBP-1 promoter 
activity (Suwanichkul et al 1994; Gan et al 2005), via the 
insulin-independent kinases (Lewitt 2001), by stabilisation 
of IGFP-1 mRNA (Luo et al 1990; Uchijima et al 1999) and 
a synergy of the glucocorticoid receptor and the hepatocyte 
nuclear factor 1 (HNF1) (Suh and Rechler 1997; Suh et al 
1995). These pathways would let us expect an increase 
of IGBP-1 in the steroid treated children. As IGFBP-1 is 
thought to decrease the effect of IGF-I (Öszkan et al 1999), 
this pathway might contribute to reduced physical growth 
in dexamethasone treated infants.
Earlier, we have shown that the ﬁ  rst months of life are 
characterized by a pole reversal of the somatotropic axis: 
IGFBP-1 and 2 decrease and IGFBP-3 increases. The ratio 
IGFBP-3/(IGFBP-1 + 2) is therefore a marker for the matura-
tion of the IGF/IGFBP axis. In infants with BPD this ratio is 
signiﬁ  cantly reduced during the ﬁ  rst 6 months of life (Hübler 
et al 2006).
As glucocorticoid treatment is linked to a signiﬁ  cantly 
reduced ratio, both in infants with and without BPD, dexa-
methasone contributes to the delay of somatic maturation in 
high risk infants.
We suggest different phases of the interaction between 
dexamethasone and the IGF/IGFBP-1 axis:
Phase 1: The metabolic decompensation after glucocorti-
cioid application causes hyperglycemia, reactive hyperinsu-
linism and eventually reduction of serum IGFBP-1.
Phase 2: Dexamethasone induces the hepatic synthesis 
of IGFBP-1.
Phase 3: After a latency serum IGFBP-1 increases. This might 
lead to an impaired equilibrium between the IGF-binding-proteins 
and therefore might contribute to endocrine dysregulation due to 
a reduced number of freely circulating IGFs.
Figure 1 IGFBP-1 [μg/l] after 3 months of corrected postnatal age in the subgroups of 
infants without bronchopulmonary dysplasia (n = 60; no glucocorticoids n = 55; glucocor-
ticoids n = 5), and with bronchopulmonary dysplasia (n = 15; no glucocorticoids n = 7; 
glucocorticoids n = 8). Results of the Mann-Whitney U-test are given for each subgroup.
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Figure 2 Box-Whisker plots of the IGFBP-3/(IGFBP-1 + 2) ratio in the subgroups 
of infants with or without a systemic administration of glucocorticoids given 
between the 2nd and 4th week after birth.
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These alterations might possibly persist (potential 
phase 4) and alter somatic growth and eventually contribute 
to metabolic syndrome and cardiovascular disease.
In our investigation, dexamethasone treatment has a 
negative impact on weight gain and head circumference. Our 
data might contribute to understand the pathophysiological 
mechanisms involved in these development, particularly the 
IGF/IGFBP axis.
It remains to speculate if low weight at the age of 
3 months might be associated with excessive weight gain 
later on and therefore with an increased risk for metabolic 
and cardiovascular disease (Barker et al 2005).
Conclusion
Dexamethasone treatment might contribute to impaired 
somatic maturation in high risk infants via alterations in the 
IGF/IGBP axis. Therefore, the use of glucocorticoids in neo-
natology should be carefully weighed. Long-term follow-up 
of our infants should evaluate further somatic development 
and cardiovascular function.
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